Brodin, P., Casari, G., Townsend, L., O’Farrelly, C., Tancevski, I., Löffler-Ragg, J.
, Mogensen, T. H., Casanova, J. L. & The COVID Human Genetic Effort (2022).
Studying severe long COVID to understand post-infectious disorders beyond COVID-19.
Nature Medicine,
28, 879-882.
https://doi.org/10.1038/s41591-022-01766-7
Manry, J., Bastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Michailidis, E., Hoffmann, H. H., Eto, S., Garcia-Prat, M., Bizien, L., Parra-Martínez, A., Yang, R., Haljasmägi, L., Migaud, M., Särekannu, K., Maslovskaja, J., de Prost, N., Tandjaoui-Lambiotte, Y. ... CoV-Contact Cohort (2022).
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Proceedings of the National Academy of Sciences (PNAS),
119(21), Article e2200413119.
https://doi.org/10.1073/pnas.2200413119
Bastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Manry, J., Michailidis, E., Hoffmann, H. H., Eto, S., Garcia-Prat, M., Bizien, L., Parra-Martínez, A., Yang, R., Haljasmägi, L., Migaud, M., Särekannu, K., Maslovskaja, J., Prost, N. D., Tandjaoui-Lambiotte, Y. ... Imagine COVID Group (2021).
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Science Immunology,
6(62), Article 4340.
https://doi.org/10.1126/sciimmunol.abl4340